Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-9273302-B2
Application number	US-201414454310-A
Country	US
Kind code	B2
Filing date	Aug 7, 2014
Priority date	Feb 16, 2012
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

First claim

The invention claimed is:

1. An aseptic immunoadsorbent composition, comprising a biocompatible solid support having attached thereto at least one histidyl-tRNA synthetase (HRS) polypeptide of 500-506 amino acids in length that is least 90% identical to SEQ ID NO:70 (HRS(1-506)) and lacks residues 507-509 of SEQ ID NO:1, wherein the HRS polypeptide has reduced interchain disulfide formation under reducing conditions relative to the polypeptide of SEQ ID NO:1 (full-length HRS).

2. The composition of claim 1 , wherein the HRS polypeptide is 505-506 amino acids in length is at least 90% identical to SEQ ID NO:70.

3. The composition of claim 1 , wherein the HRS polypeptide is 506 amino acids in length.

4. The composition of claim 1 , wherein the HRS polypeptide comprises SEQ ID NO:70.

5. The composition of claim 1 , wherein the HRS polypeptide consists essentially of SEQ ID NO:70.

6. The composition of claim 1 , wherein the HRS polypeptide consists of SEQ ID NO:70.

7. The composition of claim 1 , where the HRS polypeptide is 505 amino acids in length.

8. The composition of claim 7 , where the HRS polypeptide comprises residues 2-506 of SEQ ID NO:70 (HRS(2-506)).

9. The composition of claim 7 , where the HRS polypeptide consists essentially of residues 2-506 of SEQ ID NO:70 (HRS(2-506)).

10. The composition of claim 7 , where the HRS polypeptide consists of residues 2-506 of SEQ ID NO:70 (HRS(2-506)).

11. The composition of claim 1 , wherein the biocompatible solid support is selected from synthetic and natural polymers, polysaccharides, polyamides, glass beads, particulate silica, porous glass, silica, resins, synthetic matrixes including acrylamide derivatives, methacrylamide derivatives, and polystyrene.

12. The composition of claim 11 , wherein the polymer is selected from agar, alginate, carrageenan, guar gum, gum arabic, gum ghatti, gum tragacanth, karaya gum, locust bean gum, xanthan gum, agaroses, celluloses, pectins, mucins, dextrans, starches, heparins, chitosans, hydroxy starches, hydroxypropyl starches, carboxymethyl starches, hydroxyethyl celluloses, hydroxypropyl celluloses, and carboxymethyl celluloses.

13. The composition of claim 11 , wherein the synthetic polymer is selected from acrylic polymers, polyamides, polyimides, polyesters, polyethers, polymeric vinyl compounds, polyalkenes, and mixtures thereof.

14. The composition of claim 11 , wherein the HRS polypeptide is covalently coupled to the biocompatible support.

15. A method for extracorporeal immunoadsorption of anti-histidyl-tRNA synthetase (HRS) antibodies from an extracellular body fluid, comprising (a) providing the extracellular body fluid which has been obtained from a subject, (b) contacting the extracellular body fluid with the aseptic immunoadsorbent composition of claim 1 , thereby capturing the anti-HRS antibodies on the solid support, and (c) re-infusing the extracellular body fluid from step (b) into the subject.

16. The method of claim 15 , where the anti-HRS antibodies include a Jo-1 antibody.

17. The method of claim 15 , wherein the contact temperature in the range of 35° C. to about 40° C.

18. The method of claim 15 , wherein the contact time of the extracellular body fluid with the biocompatible support is within the range of about 1 to about 6 hours.

19. The method of claim 15 , wherein extracorporeal immunoadsorption is carried out immediately prior to administration of a HRS polypeptide.

20. The method of claim 15 , wherein extracorporeal immunoadsorption is capable of removing greater than 90% of the circulating antibodies in a single pass from a 1 in 1,000 dilution of Jo-1 positive human serum.

21. The method of claim 20 , wherein extracorporeal immunoadsorption is capable of removing greater than 95% of the circulating antibodies in a single pass from a 1 in 1,000 dilution of Jo-1 positive human serum.

Assignees

• Atyr Pharma Inc
• Pangu Biopharma Ltd

Inventors

• Chiang Kyle P
• Gardiner Elisabeth
• Lau Ching-Fun
• Lo Wing-Sze
• Greve Jeffrey
• Ashlock Melissa
• Mendlein John D

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title